Ovarian cancer, version 2.2013

These NCCN Guidelines Insights focus on the major updates to the 2013 NCCN Guidelines for Ovarian Cancer. Four updates were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials. The topics include 1) intraperitoneal chemotherapy,...

Full description

Saved in:
Bibliographic Details
Published inJournal of the National Comprehensive Cancer Network Vol. 11; no. 10; p. 1199
Main Authors Morgan, Jr, Robert J, Alvarez, Ronald D, Armstrong, Deborah K, Burger, Robert A, Chen, Lee-may, Copeland, Larry, Crispens, Marta Ann, Gershenson, David M, Gray, Heidi J, Hakam, Ardeshir, Havrilesky, Laura J, Johnston, Carolyn, Lele, Shashikant, Martin, Lainie, Matulonis, Ursula A, O'Malley, David M, Penson, Richard T, Powell, Matthew A, Remmenga, Steven W, Sabbatini, Paul, Santoso, Joseph T, Schink, Julian C, Teng, Nelson, Werner, Theresa L, Dwyer, Mary A, Hughes, Miranda
Format Journal Article
LanguageEnglish
Published United States 01.10.2013
Subjects
Female
Humans
Ovarian Neoplasms - diagnosis
Ovarian Neoplasms - therapy
Recurrence
Online AccessGet more information

Cover

More Information
Summary:These NCCN Guidelines Insights focus on the major updates to the 2013 NCCN Guidelines for Ovarian Cancer. Four updates were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials. The topics include 1) intraperitoneal chemotherapy, 2) CA-125 monitoring for ovarian cancer recurrence, 3) surveillance recommendations for less common ovarian histopathologies, and 4) recent changes in therapy for recurrent epithelial ovarian cancer. These NCCN Guidelines Insights also discuss why some recommendations were not made.
ISSN:1540-1413
DOI:10.6004/jnccn.2013.0142